Randomized trial · people
Survodutide: 12.2% weight loss and less liver fat at 48 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This phase 3 trial adds evidence that survodutide lowered liver fat and body weight more than placebo over 48 weeks in adults with obesity and at-risk fatty liver disease, with mostly gastrointestinal side effects.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 216
- Published
- 2026
- Journal
- Nat Med
What they tested
The team tested whether survodutide lowers liver fat and body weight more than placebo in adults with obesity and at-risk fatty liver disease.
How the study was done
A phase 3 randomized, double-blind, placebo-controlled trial in 216 adults with obesity and at-risk MASLD (fatty liver disease tied to metabolic problems, with signs of liver inflammation or scarring). Participants got weekly injections of survodutide 6.0 mg or placebo (a dummy shot) in a 2:1 ratio for 48 weeks, at sites in the United States and Spain.

Model. Individual results vary.
What they found
At 48 weeks, 84.2% of people on survodutide had at least a 30% drop in liver fat on MRI-PDFF (an MRI measure of liver fat), compared with 24.3% on placebo, using the trial's efficacy estimand; with the treatment regimen estimand, the figures were 68.5% versus 28.6%. Body weight changed by -12.2% with survodutide and -1.0% with placebo by the first method, and by -8.7% versus -1.4% by the second. All of these differences had P < 0.0001. The most common side effects were gastrointestinal, often during dose increases, and mostly mild to moderate.
What it doesn’t show
The trial lasted only 48 weeks and enrolled people only in the United States and Spain. It tested a single dose, 6.0 mg, against placebo.
The paper
Kaplan et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026.
The compound
More studies on Survodutide
- Survodutide: up to 14.9% weight loss at 46 weeks in phase 2 trialRandomized trial · people · 2024
- Every study on Survodutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.